Can low-grade inflammation increase demand for omega-3-derived resolving mediators?

Innate immune activation and SPM demand

• Chronic low-grade inflammation and persistent innate immune activation significantly increase the biological demand for specialized pro-resolving mediators (SPMs), such as resolvins, protectins, and maresins.
• During acute inflammation, a healthy physiological response relies on a coordinated "class switch" from pro-inflammatory eicosanoids to SPMs to actively terminate the inflammatory response. In chronic inflammatory states, this resolving cascade is disrupted, allowing persistent pro-inflammatory signaling to continuously outpace the body’s resolving capacity.

Mechanistic bottlenecks in resolving capacity

• The functional depletion of resolving capacity during chronic inflammation is primarily driven by rate-limiting enzymatic bottlenecks rather than a simple shortage of parent omega-3 fatty acid substrates (EPA and DHA).
• The biosynthesis of SPMs is a highly restricted, low-flux pathway. Key enzymes, specifically 5-lipoxygenase (5-LOX) and 15-lipoxygenase (15-LOX), serve as strict biosynthetic checkpoints.
• Because this enzymatic machinery operates at a naturally low capacity, it is easily overwhelmed by high-volume eicosanoid production. Under sustained innate immune activation, the utilization of resolving mediators outpaces the capacity of these low-flux enzymatic circuits to synthesize them.
• This localized deficiency in SPM synthesis prevents the proper completion of the resolution program, transforming acute defensive responses into a self-perpetuating cycle of chronic, low-grade tissue inflammation.

Bottom line

• Persistent low-grade inflammation increases the biological demand for omega-3-derived SPMs. Because resolving mediator synthesis is limited by strict enzymatic bottlenecks (5-LOX/15-LOX) rather than substrate availability alone, inflammatory utilization can easily outpace resolving capacity, leading to a self-perpetuating inflammatory state.